-
Mashup Score: 0Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin’s Lymphoma | NEJM - 1 year(s) ago
Original Article from The New England Journal of Medicine — Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk Hodgkin’s Lymphoma
Source: New England Journal of MedicineCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
PURPOSE To evaluate the outcomes and cost-effectiveness of the Children’s Oncology Group Guideline recommendation for breast cancer (BC) screening using mammography (MAM) and breast magnetic resonance imaging (MRI) in female chest-irradiated childhood Hodgkin lymphoma (HL) survivors. Digital breast tomosynthesis (DBT), increasingly replacing MAM in practice, was also examined. METHODS Life years…
Source: Journal of Clinical OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
💰 #BreastCancer screening using abbreviated breast #MRI & #mammography is #CostEffective in chest-irradiated childhood #HodgkinsLymphoma #Survivors 👉 https://t.co/pWpKf8nClL #JCO #Survivorship #BCSM #pedcsm #hpeonc #oncorad #survonc @SmitaBhatia10 https://t.co/ymMTQPy2Si
-
-
Mashup Score: 3Development and Validation of Risk Prediction Models for Coronary Heart Disease and Heart Failure After Treatment for Hodgkin Lymphoma - 2 year(s) ago
PURPOSE Previous efforts to predict absolute risk of treatment-related cardiovascular diseases (CVDs) have mostly focused on childhood cancer survivors. We aimed to develop prediction models for risk of coronary heart disease (CHD) and heart failure (HF) for survivors of adolescent/adult Hodgkin lymphoma (HL). METHODS For model development, we used a multicenter cohort including 1,433 5-year HL…
Source: Journal of Clinical OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🫀 Absolute risk models provide long-term estimates to identify survivors of #HodgkinsLymphoma at high risk for #CoronaryArteryDisease and #HeartFailure 👉 https://t.co/2qjBUE5wiO #JCO #lymsm #cardioonc #CAD #HF https://t.co/BwawO6qmbs
-
-
Mashup Score: 0Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma | NEJM - 2 year(s) ago
Original Article from The New England Journal of Medicine — Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma
Source: New England Journal of MedicineCategories: Hem/Oncs, Latest HeadlinesTweet-
Overall Survival with #Brentuximab #Vedotin in Stage III or IV #HodgkinsLymphoma "Patients who received A+AVD... had a survival advantage over those who received ABVD"👇 https://t.co/uQyZeVrvNf @DrDavidStraus @KLFenton #StageIII #StageIV https://t.co/habp71d9UI
-
-
Mashup Score: 2Lymphoma Daily - 2 year(s) ago
Content directly from sources and does not necessarily reflect my views by Jason R Westin
Source: paper.liCategories: Hem/Oncs, Latest HeadlinesTweet-
The latest Lymphoma Daily! https://t.co/IRC7TpZFmA Thanks to @TheHourNews @LLSusa @Patient_Story #hodgkinslymphoma #cancer
-
-
Mashup Score: 10Treatment Strategies for Advanced Classical Hodgkin Lymphoma in the Times of Dacarbazine Shortage - 2 year(s) ago
The shortage of dacarbazine (DTIC) has created an acute and unprecedented crisis in the management of patients with classical Hodgkin lymphoma, with DTIC being an essential component of doxorubicin, bleomycin, vinblastine, and DTIC (ABVD) and prior attempts at omitting DTIC from ABVD leading to substantial loss of efficacy. In this review, we discuss the strategies to manage classical Hodgkin…
Source: JCO Oncology PracticeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
This #JCOOP clinical review provides much-needed guidance on how to treat advanced stage #HodgkinsLymphoma during dacarbazine shortage on the basis of pt fitness & ability to receive anthracyclines safely. https://t.co/O9HTnCZrBs #lymsm #lymphoma @PallawiTorkaMD https://t.co/GhfF1qNXya
-
-
Mashup Score: 0Phase 3 Study Supports Pembrolizumab in Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma - 3 year(s) ago
The interim analysis from the phase 3 KEYNOTE-204 study suggests pembrolizumab should be considered the preferred treatment option for patients with relapsed or refractory classical Hodgkin lymphoma over brentuximab vedotin.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The interim analysis from the phase 3 KEYNOTE-204 study suggests pembrolizumab should be considered the preferred treatment option for patients with relapsed or refractory classical Hodgkin lymphoma over brentuximab vedotin. #hodgkinslymphoma https://t.co/1xRAwbzIx1
-
-
Mashup Score: 0Lymphoma Daily - 3 year(s) ago
Content directly from sources and does not necessarily reflect my views by Jason R Westin
Source: paper.liCategories: Hem/Oncs, Latest HeadlinesTweet-
The latest Lymphoma Daily! https://t.co/wGOn3fKib7 Thanks to @MicheleNadeemB @Meadowolf69 @RNorris02 #hodgkinslymphoma #rojeamccook
-
-
Mashup Score: 0
Miles Prince, MD of Peter MacCallum Cancer Centre discusses the ASH 2020 abstract – The ECHELON-2 Trial: 5-year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma.IntroducingThe phase 3 ECHELON-2 analysis (NCT01777152) showed that frontline therapy with brentuximab…
Source: www.oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The ECHELON-2 Trial: 5-year Results of a Randomized, Double-Blind, Phase 3 Study Miles Prince, MD @MilesPrince4 @PeterMacCC #ASH20 #HodgkinsLymphoma #Cancer #Research Link To FULL Video: https://t.co/rIuWhhgZCj https://t.co/1Ls5dyYPwK
-
-
Mashup Score: 1
Mehul Dalal, Ph.D. Takeda Oncology discusses ASH 2020 abstract – 2979 Results from the International, Multi-Center, Retrospective B-Holistic Study: Describing Treatment Pathways and Outcomes for Classical Hodgkin Lymphoma.Context:Just half of the patients with relapsed/refractory (R/R) cHL are cured with salvage chemotherapy accompanied by stem cell transplantation, prompting clinical…
Source: www.oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Describing Treatment Pathways and Outcomes for Classical Hodgkin Lymphoma Mehul Dalal, Ph.D. @TakedaOncology #ASH20 #hodgkinslymphoma #cancer #research Link To FULL Video: https://t.co/zdi1yVROPC https://t.co/Wxy4uiJI35
-
#Brentuximab Vedotin with Chemotherapy in Pediatric High-Risk #HodgkinsLymphoma👇 https://t.co/sssMVzXlGK @SharonCastelli2 @HoppeBrad @DrDHodgson #Doxorubicin https://t.co/u1VQRNlpNT